Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price hit a new 52-week high on Tuesday after Wedbush raised their price target on the stock from $43.00 to $58.00. Wedbush currently has an outperform rating on the stock. Maze Therapeutics traded as high as $53.65 and last traded at $51.26, with a volume of 899720 shares changing hands. The stock had previously closed at $50.21.

A number of other equities research analysts also recently commented on the stock. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price for the company. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Guggenheim raised their price target on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Finally, Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $57.38.

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares in the company, valued at $426,001.68. This represents a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 230,000 shares of company stock valued at $9,768,292 in the last ninety days.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC lifted its stake in shares of Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after buying an additional 915,342 shares during the period. Marshall Wace LLP increased its stake in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after buying an additional 758,104 shares in the last quarter. Caligan Partners LP bought a new stake in Maze Therapeutics during the fourth quarter valued at about $22,794,000. Finally, ArrowMark Colorado Holdings LLC bought a new stake in Maze Therapeutics during the third quarter valued at about $14,135,000.

Maze Therapeutics Price Performance

The firm has a market capitalization of $2.47 billion, a PE ratio of -2.45 and a beta of 4.46. The company has a 50-day moving average price of $45.07 and a 200 day moving average price of $36.16.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.